A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancers
Cancer · 15.05.2024 · 130 (10) · 1733-1746
DOI: 10.1002/cncr.35267 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 29.02.2024. Verfasst von Ying L Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Endometrial Neoplasms, Microsatellite Instability, DNA Mismatch Repair. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The DNA mismatch repair (MMR) pathway is critical for correcting DNA mismatches generated during DNA replication. MMR‐deficiency (MMR‐D) leads to microsatellite instability (MSI) associated with an increased mutation rate, driving cancer development. This is particularly relevant in endometrial cancer (EC) as 25%–30% of tumors are of MMR‐D/MSI‐high (MSI‐H) phenotype. Comprehensive assessment using immunohistochemistry (IHC) and sequencing‐based techniques are necessary to fully evaluate ECs given the importance of molecular subtyping in staging and prognosis. This also influences treatment selection as clinical trials have demonstrated survival benefits for immune checkpoint inhibitors (ICIs) alone and in combination with chemotherapy for MMR‐D/MSI‐H EC patients in various treatment settings. As a portion of MMR‐D/MSI‐H ECs are driven by Lynch syndrome, an inherited cancer predisposition syndrome that is also associated with colorectal cancer, this molecular subtype also prompts germline assessment that can affect at‐risk family members. Additionally, heterogeneity in the tumor immune microenvironment and tumor mutation burden (TMB) have been described by MMR mechanism, meaning MLH1 promoter hypermethylation versus germline/somatic MMR gene mutation, and this may affect response to ICI therapies. Variations by ancestry in prevalence and mechanism of MMR‐D/MSI‐H tumors have also been reported and may influence health disparities given observed differences in tumors of Black compared to White patients which may affect ICI eligibility. These observations highlight the need for additional prospective studies to evaluate the nuances regarding MMR‐D heterogeneity as well as markers of resistance to inform future trials of combination therapies to further improve outcomes for patients with EC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Ying L Liu, Britta Weigelt
Förderung
- NCI NIH HHS
Zitieren
APA
Liu, Y. L., & Weigelt, B. (2024). A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancers. Cancer, 130(10), 1733-1746. https://doi.org/10.1002/cncr.35267
Vancouver
Liu YL, Weigelt B. A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancers. Cancer. 2024;130(10):1733-1746. doi:10.1002/cncr.35267
BibTeX
@article{Liu2024,
author = {Liu, Ying L and Weigelt, Britta},
title = {A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancers},
journal = {Cancer},
year = {2024},
volume = {130},
number = {10},
pages = {1733--1746},
doi = {10.1002/cncr.35267}
}
EUVIMED